Gelesis pioneered a biomimetic approach using naturally-derived hydrogels that mechanically expanded in the stomach to create satiety without systemic effects. The company pursued a diverse pipeline including Gelesis200 for Type 2 Diabetes and investigational candidates for NASH and functional constipation. Despite FDA approval and clinical validation, commercialization challenges and market headwinds led to financial distress.
Cyborg Score Rationale
While the company achieved FDA approval for Plenity and demonstrated clinical efficacy, it faced severe commercialization challenges, resulting in liquidation in October 2023. The company's revenue of $12.1M (as of mid-2023) was insufficient to support operations, and it accumulated significant losses despite raising $200.48M over its history.
Top Insights
FDA-approved product (Plenity) achieved regulatory milestone in April 2019 but faced limited commercial uptake and restricted distribution
Innovative biomimetic approach using naturally-derived superabsorbent hydrogels with demonstrated metabolic benefits beyond mechanical satiety (GLP-1 induction, improved insulin sensitivity)
Comprehensive pipeline spanning obesity, Type 2 Diabetes, NASH, and functional constipation indicated broad therapeutic ambition but diluted focus during distress
Company filed for Chapter 7 liquidation in October 2023, rendering current status inactive; historical analysis only
Named Competitors
Vivus Weight Loss Products — Oral medications for weight management
Novo Nordisk GLP-1 Agonists (semaglutide) — Injectable GLP-1 receptor agonists for weight loss and diabetes
Eli Lilly GLP-1 Agonists (tirzepatide) — GLP-1/GIP receptor agonists for weight loss and diabetes
NGM Biopharmaceuticals Therapies — Biologic drug candidates for metabolic diseases
Recent Developments
(January 2022) Completed business combination with Capstar Special Purpose Acquisition Corp., enabling public listing
(April 2019) Received FDA clearance for Plenity as weight management aid
(October 2023) Filed for voluntary Chapter 7 liquidation—company no longer operating
Open the full interactive Gelesis Holdings, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.